Clinical Trial

A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

Name: A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07735546)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT07735546
Lead Sponsor	Umoja Biopharma
Conditions	Multiple Myeloma in Relapse, Multiple Myeloma (MM)
Enrollment	100 participants
Start Date	2026-10-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-30